Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 23ME-00610 |
Synonyms | |
Therapy Description |
23ME-00610 is a monoclonal antibody targeting CD200R1, which potentially results in increased antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 602). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
23ME-00610 | 23ME00610|23ME 00610 | 23ME-00610 is a monoclonal antibody targeting CD200R1, which potentially results in increased antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 602). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |